Chardan Capital Has Bullish Outlook for UBX FY2025 Earnings

Unity Biotechnology, Inc. (NASDAQ:UBX) – Stock analysts at Chardan Capital boosted their FY2025 EPS estimates for Unity Biotechnology in a research note issued on Monday, March 10th. Chardan Capital analyst D. Gataulin now anticipates that the company will post earnings per share of ($0.72) for the year, up from their previous forecast of ($0.74). Chardan Capital currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Unity Biotechnology in a research report on Monday.

Unity Biotechnology Stock Performance

NASDAQ UBX opened at $1.79 on Thursday. Unity Biotechnology has a fifty-two week low of $0.94 and a fifty-two week high of $3.10. The company has a market cap of $30.16 million, a P/E ratio of -1.37 and a beta of 1.02. The business’s 50 day moving average price is $1.88 and its 200-day moving average price is $1.51.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Unity Biotechnology stock. Geode Capital Management LLC increased its position in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 9.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 163,242 shares of the company’s stock after purchasing an additional 14,199 shares during the quarter. Geode Capital Management LLC owned approximately 0.97% of Unity Biotechnology worth $240,000 as of its most recent filing with the SEC. 29.49% of the stock is owned by hedge funds and other institutional investors.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.